Skip to main content
OpenTrials
Completed

NCT Number: NCT00709514

Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers

The primary objective of this Phase 2 study is to evaluate the efficacy of DCB-WH1 ointment in wound closure as compared to vehicle control when applied topically to chronic diabetic foot ulcers for 12 weeks. The secondary objective of this study is to collect safety information of DCB-WH1 ointment.

This is a randomized, double-blind, parallel group, vehicle-controlled, multi-center study of DCB-WH1 ointment applied topically to grade 1 foot ulcers (according to Wagner grading system) in 50 subjects with diabetes mellitus.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 20 or older with diabetes mellitus (Type 1 or 2) who has a cutaneous ulcer on the foot and present for at least 2 weeks
  • The target ulcer is classified as a grade 1 ulcer according to a modified Wagner system, which includes wounds involving the epidermis, the dermis, the hypodermis or the subcutaneous fat but not the tendon or joint capsule. The thickness of aforesaid layers wounds be approximately between 0.2 mm and 8 mm and is ranging in size between 3 and 15 cm2 post debridement.
  • An ankle brachial index ≥0.80.
  • The study ulcer should show "infection control" as judged by the investigator
  • The subject should be free of any necrotic or infected soft and bony tissue.
  • Signed informed consent form.

Exclusion criteria

  • Ulcers caused by venous or arterial insufficiency, osteomyelitis.
  • Poor nutritional status (albumin < 3g/dl), poor diabetic control (HbA1c > 10%), anemia (hemoglobin<10 g/dL), a leukocyte counts < 1,000/cumm.
  • Requiring prostaglandin treatment.
  • Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, radiotherapy.
  • Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement.
  • Presence of connective tissue disease, renal failure (*eGFR≦30 ml/min/1.73m2), abnormal liver function (Aspartate Aminotransferase(AST), Alanine Aminotransferase(ALT)>2.5x upper limit of normal range), malignancy.
  • vascularization surgery performed <8 weeks before entry in the study.
  • A history of cerebrovascular events, coronary intervention (stent or coronary artery bypass graft (CABG)) or myocardial infarction, within 6 months prior to study.
  • Female patient who has a positive pregnancy test or who is breastfeeding or unwilling to use appropriate contraceptive methods during study.

Treatment and study plan

DCB-WH1 ointment

Drug

DCB-WH1 ointment (1.25%), topically applied twice daily

Placebo

Drug

Placebo

Primary outcomes

  1. The incidence of complete ulcer closure

    Time frame: 12 weeks

Secondary outcomes

  1. The time of healing rate and change in ulcer area

    Time frame: 12 weeks

    time to ulcer closure, time to half ulcer closure, ulcer closure rate at endpoint, change and percentage change from baseline in ulcer size

Sponsors and collaborators

Lead sponsor

Oneness Biotech Co., Ltd.

Industry

Registry information

Official study title

A Phase II, Double-blind, Placebo-controlled Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers

Important dates

Study start
2008
Primary completion
2011
Study completion
2012
First posted
Jul 3, 2008
Registry last updated
Jul 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.